A Study on Changes of Metabolic Parameters with Antipsychotic Treatment in Schizophrenic Patients : 1 Year Prospective Natualistic Study.
10.16946/kjsr.2015.18.2.59
- Author:
Sun Hwa JEONG
1
;
Seon Jin YIM
;
Hai Joo YOON
;
Eun Kyung PARK
;
Jong Il LEE
Author Information
1. Department of Psychiatry, Seoul National Hospital, Seoul, Korea. lji7542@naver.com
- Publication Type:Original Article
- Keywords:
Schizophrenia;
Atypical antipsychotic drugs;
Metabolic parameters
- MeSH:
Antipsychotic Agents;
Blood Glucose;
Blood Pressure;
Case Management;
Cholesterol;
Diagnosis;
Diet;
Fasting;
Follow-Up Studies;
Humans;
Medical Records;
Metabolic Diseases;
Obesity, Abdominal;
Prescriptions;
Prevalence;
Prolactin;
Prospective Studies*;
Psychotropic Drugs;
Schizophrenia;
Triglycerides
- From:Korean Journal of Schizophrenia Research
2015;18(2):59-65
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: Schizophrenia patients are known to be more prone to metabolic disease than normal people. This study aimed to identify the changes in metabolic parameters of schizophrenia patients using atypical antipsychotic drugs for 1 year. METHODS: A total of 200 schizophrenia patients were recruited and categorized into the aripiprazole-treatment group and control group taking 5 atypical antipsychotic drugs. Comparative analysis were between groups. The prescriptions of psychotropic drugs were collected by a review of medical records. Blood was collected after fasting for 12 hours at the starting point of treatment and the 12th month, and patient medical records were evaluated for basici nformation and treatment history. Physical measurement, the prevalence of metabolic syndrome and metabolic parameters were studied using ATP-III diagnostic criteria. RESULTS: From the study, the aripiprazole-treatment group had a mean weight increase of 0.6 kg and the control group had a mean weight increase of 6.5 kg at the 1 year follow-up, showing a significant difference between the two groups. There were also significant differences between the two groups in waist size, systolic and diastolic blood pressure, fasting blood sugar, total cholesterol, triglyceride, HDL-choleseterol and prolactin level. Along with meaningful improvement of the symptoms, aripiprazole-treatment group showed less effect on in abdominal obesity, diabetes, blood pressure, cholesterol and prolactin than other atypical antipsychotic drugs. CONCLUSION: Therapeutic intervention such as diagnosis, treatment, weight management and diet improvement is necessary for schizophrenia patients. Psychiatric symptoms as well as internal meicine-related problems such as metabolic disease need to be addressed in case management.
